Dr. Nick N Gorgani

Dr. Nick N Gorgani |Clyto Access

President and CEO at GlyConMedics, LLC, USA

Keynote Speaker

Expertise: type 2 diabetes mellitus


Dr. Gorgani, PhD is the inventor of a new treatment for type 2 diabetes mellitus and the founder and CEO of OzStar Therapeutics and GlyConMedics, LLC. He has a multidisciplinary background spanning chemical engineering to medicine to immunology and to industrial drug development. He has worked for academic institutions, hospitals, biotechnology and pharmaceutical companies. He contributed to numerous classes of patentable discoveries including, non-inflammatory disposal of pathogens and dying cells, a new biologic for the treatment of RA and AMD, mechanism of action of a small molecule that mediates immune tolerance and a world first-in-class small molecule to treat proteinuria.



Title: Improving Clinical Outcomes in Type 2 Diabetes Patients on Sulfonylurea Drugs


Type 2 diabetes mellitus (T2DM) patients are prescribed with a number of oral and injectable medications, each of which has significant side effects. Whilst side effects such as hypoglycemia, weight gain and gastro-intestinal tolerability are associated with older anti-diabetes agents, the newly marketed drugs are associated with tolerability and safety issues including increased risk of infections, pancreatitis, bone fractures, fluid retention, amputation and congestive heart failure. The currently marketed anti-diabetes drugs generally have limited efficacy, necessitating multiple drugs to control most patient’s glycaemia. Consequently, due to intake of multiple drugs, each having their own side effects, as well as the progressive nature of the disease, T2DM patients may experience a multitude of side effects. Thus, T2DM remains a challenge and there is a need for better, safer and ideally cheaper treatments.

We are developing an adjunctive treatment to a very well-established and widely prescribed sulfonylurea class of anti-diabetes drugs to reduce the risk of its clinically significant side effects and to extend its efficacy. We’ve hypothesized that while sulfonylurea exerts anti-diabetes efficacy, it also exerts anti-biotic effects, because sulfonylurea are derivatives of sulfonamide anti-biotics. While sulfonylurea efficiently control blood glucose, its chronic use and anti-biotic properties inadvertently reduces “gut microbiome” diversity. The latter leads to evolution of two major side effects and loss of glycemic efficacy within 6-12 months. We speculate that the anti-biotic effects of sulfonylurea might be ameliorated by increasing the gut microbiome diversity through the adjunctive intake of certain prebiotics.

To test this hypothesis, we have conducted clinical case studies and assessed a number of different naturally-derived prebiotic products, of which one specific prebiotic synergized with sulfonylurea, but not with non-sulfonylurea, anti-diabetes drugs. This adjunctive treatment significantly ameliorate sulfonylurea’s major side effects such as hypoglycemia and weight gain and extends duration and strength of its efficacy.


Related Conferences :

International Diabetes and Degenerative Diseases Conference